The BPC-157 + TB-500 Combination Protocol | telos rx
The BPC-157 + TB-500 Combination Protocol
← Back to blog

The BPC-157 + TB-500 Combination Protocol

By TelosRX Editorial Team Updated

The BPC-157 plus TB-500 combination protocol is the one way telos rx currently makes TB-500 available. It is worth understanding exactly what that means before starting an intake.

What to know

The BPC-157 plus TB-500 combination protocol is a stack supplied as two separate vials, one of BPC-157 and one of TB-500, available through telos rx. telos rx does not offer TB-500 on its own.

Start the BPC-157 + TB-500 combo intake →

What the combination protocol is

The BPC-157 plus TB-500 combination protocol pairs two peptides, compounded BPC-157 and TB-500, under one reviewed stack, supplied as two separate vials. Each vial holds a single active ingredient and is prepared by telos rx's partner compounding pharmacies. It follows the same review process telos rx applies to its other compounded peptide offerings.

This is different from leaving a patient to piece the two together. A provider reviews the stack as one plan covering both vials, and each vial arrives ready to inject at the prescribed dose, with nothing to mix and no dose to calculate. Your provider sets how each one is used.

How it relates to standalone TB-500's regulatory status

FDA placed TB-500 in its Category 2 list of bulk substances in September 2023 and removed it on April 22, 2026. On October 28, 2026, HHS announced a temporary enforcement discretion policy for six peptides, BPC-157 and TB-500 among them (Federal Register notice). It covers each peptide only as a single-ingredient product compounded by a state-licensed pharmacy with a valid prescription and strict sourcing, testing and reporting conditions, so it does not extend to a formulation that combines the two in one product. It is not FDA approval, it lasts only while FDA completes rulemaking, and HHS can revisit it. The telos rx stack is supplied as two separate vials, so neither vial is a blend. telos rx does not currently offer standalone TB-500.

This distinction is genuinely important to understand if you are researching TB-500 specifically. Interest in this stack should be based on the stack itself, not treated as a workaround to obtain TB-500 alone through a different label.

Who typically looks into this protocol

People researching this combination are usually already familiar with BPC-157 and TB-500 individually. That familiarity often comes from recovery-focused research communities. They are curious whether a combined approach might suit their goals differently than either peptide alone.

A licensed provider is the right person to walk through whether that reasoning applies to your specific situation. Appropriateness depends on individual history and goals, rather than general assumptions about stacks working better simply because two peptides are involved.

How the intake process works

Like telos rx's other compounded peptide offerings, the combination protocol intake is asynchronous. You complete an online intake, and a licensed provider reviews your history. Approval is subject to that clinical review rather than automatic based on the request alone.

Anyone considering this protocol should also review the BPC-157 + TB-500 combination page for the most current details on what telos rx offers. Specifics can be updated as the program evolves, so it is worth checking before you start.

What the combination protocol does not claim

The combination protocol is described honestly as a stack built around two studied peptides. It is not framed as a promised outcome. Much of the research behind BPC-157 and TB-500 remains at a preclinical stage, meaning laboratory and animal research rather than large controlled human trials.

telos rx does not present this combination as clinically proven to produce a specific result. A licensed provider can discuss what current research does and does not support, so your expectations are grounded in an honest picture rather than marketing language.

How it compares to other options at telos rx

If the combination protocol is not the right fit, telos rx also offers standalone compounded BPC-157. Some patients prefer this if their interest is specifically in that peptide, rather than the pairing with TB-500.

Patients interested in recovery-adjacent support more broadly sometimes also look at sermorelin, a growth-hormone-releasing peptide available today through telos rx. Reviewing all three options with a provider is a reasonable way to decide which, if any, fits your goals.

What to expect after starting

Once a provider approves the combination protocol, the prescription is routed to a partner compounding pharmacy for preparation. Shipping and handling follow the same process telos rx uses for its other compounded peptide products.

Ongoing questions about the protocol, including anything unclear about dosing or administration, should go through your care team rather than being pieced together from outside sources. That keeps guidance specific to your prescription rather than a general assumption about the peptides involved.

How the combination protocol was developed

A stack like this one is not created casually. A compounding pharmacy and prescribing team typically review available research on each component and consider how the two peptides are proposed to interact. The result is two separate single-ingredient vials, reviewed as one stack.

It reflects a deliberate decision to keep each peptide in its own vial and treat the pairing as a single offering, subject to its own clinical review.

That is part of why telos rx can describe the combination protocol as available while being equally clear that standalone TB-500 is not, without any contradiction between the two statements.

Setting realistic expectations before you start

Before beginning any compounded peptide protocol, it helps to have a realistic sense of what is and is not established. BPC-157 and TB-500 are both peptides with an active but still developing research base, not settled, fully proven treatments.

A licensed provider can walk through what current research does and does not show, and can answer specific questions about your own health history during intake. That conversation is a better foundation for a decision than general claims found on forums or unregulated seller pages.

Setting expectations honestly from the start also makes it easier to have a useful follow-up conversation with your care team later, since you will know what you were actually told going in.

Sourcing and quality behind the stack

Compounded medication quality depends heavily on the pharmacy preparing it, not just the peptides involved. telos rx works only with partner compounding pharmacies that operate within current regulatory guidance and maintain their own quality processes.

This matters more, not less, for a stack, since it depends on consistent preparation of two separate vials rather than one. Asking a provider how each vial's quality is verified is a reasonable question, and one a legitimate pharmacy should be able to answer clearly.

Sourcing quality is a separate question from clinical appropriateness, but both matter. A well-sourced product prescribed for the wrong reasons is not a good outcome, and neither is a well-matched prescription filled by an unreliable pharmacy. telos rx's LegitScript certification is one signal of that reliability, though it is worth asking direct questions of any provider you work with.

Who should not consider this protocol

Like any compounded medication, the combination protocol is not automatically appropriate for everyone who is curious about it. A licensed provider reviews individual health history specifically to catch situations where a protocol would not be a good fit.

This is one reason telos rx's intake process is not a simple checkout. It is a clinical review designed to catch mismatches between a product and a patient before anything is prescribed. Being declined is not a failure. It is the review process working as intended.

If you have questions about your own eligibility before starting intake, raising them directly with the care team is more useful than guessing based on general information. Every situation is reviewed individually, and a general article cannot substitute for that specific review.

Where to read more, from primary sources

For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.

Frequently Asked Questions

What exactly is in the BPC-157 plus TB-500 combination protocol?

It pairs compounded BPC-157 with TB-500 as two separate vials, one of each peptide, prepared by telos rx's partner compounding pharmacies. Each vial holds a single active ingredient and arrives ready to inject at the prescribed dose, and your provider sets how each one is used.

Is this the same as getting TB-500 alone?

No. telos rx does not currently offer standalone TB-500. The combination protocol is a separately reviewed stack of two vials, not standalone TB-500 dispensed independently under a different name. The October 28, 2026 HHS interim enforcement discretion policy covers BPC-157 and TB-500 only as single-ingredient products, not as a combined formulation. The telos rx stack is supplied as two separate vials, so neither vial is a blend.

How do I start the intake for this protocol?

You complete telos rx's standard online intake, and a licensed provider reviews your history before any approval. The process mirrors telos rx's other compounded peptide offerings closely.

Can I request BPC-157 and TB-500 as two separate prescriptions instead?

Standalone TB-500 is not part of the telos rx program today. It is only offered through the reviewed stack described on this page, not as an individually dispensed product.

Is the combination protocol right for everyone interested in these peptides?

Not necessarily. Suitability depends on your individual history and goals, which is why a licensed provider reviews each intake rather than approving requests automatically without clinical review of your specific situation.

Where can I find the most current details on this protocol?

The BPC-157 plus TB-500 combination page on telosrx.com is the most current source. Program details can be updated over time as regulatory status evolves and as telos rx's partner pharmacies refine how each vial is prepared.

telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Questions about the BPC-157 + TB-500 combination protocol? Message the telos rx care team or read more on the BPC-157 + TB-500 combination page.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX